|The following article features coverage from the ASCO Genitourinary Cancers Symposium 2022. Click here to read more of Cancer Therapy Advisor’s conference coverage.|
Preoperative sarcopenia in patients undergoing radical nephrectomy and tumor thrombectomy for metastatic renal cell carcinoma (mRCC) is associated with major surgical complications within 3 and 12 months, according to data presented at the ASCO Genitourinary Cancers Symposium 2022.
“Screening for sarcopenia preoperatively may assist in identifying patients at high-risk for increased perioperative morbidity, which ultimately may permit the implementation of preventive therapeutic strategies,” investigators concluded in a study abstract.
Eric Midenberg, MD, of Emory University in Atlanta, Georgia, and colleagues examined the relationship between sarcopenia and major surgical complications in a study of 99 patients who had mRCC with inferior vena cava involvement who underwent radical nephrectomy and tumor thrombectomy from 2005 to 2020.
The median time from preoperative imaging to surgery was 22 days. Of the 57 (58%) patients with preoperative sarcopenia, 19 (33%) and 20 (35%) patients experienced a major surgical complication within 3 and 12 months after surgery, respectively, and 34 (60%) patients had a length of stay of 7 days or more. Preoperative sarcopenia was significantly associated with 4.8- and 6.4-fold increased odds for a major complication within 3 months and 12 months, respectively.
Sarcopenia did not significantly affect the likelihood a hospital stay of 7 days or longer after nephrectomy.
For patients with a body mass index (BMI) less than 30 kg/m2, the investigators defined sarcopenia as a skeletal muscle index (SMI) less than 47 cm2/m2 for men and less than 38 cm2/m2 for women; for patients with a BMI of 30 kg/m2 or higher, they defined sarcopenia as an SMI less than 54 cm2/m2 for men and less than 47 cm2/m2 for women.
Disclosures: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.
Read more of Cancer Therapy Advisor’s coverage of ASCO GU 2022 by visiting the conference page.
Midenberg E, Medlinie A, Patil DH, et al. Sarcopenia as a predictor of perioperative morbidity in metastatic renal cell carcinoma patients undergoing radical nephrectomy and IVC tumor thrombectomy. Presented at ASCO GU 2022; February 17-19, 2022. Abstract 388.
This article originally appeared on Renal and Urology News